Eli Lilly and Company (NYSE:LLY) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 373,844 shares of the company’s stock after selling 2,892 shares during the quarter. Eli Lilly and Company makes up about 1.1% of Calamos Advisors LLC’s holdings, making the stock its 10th largest position. Calamos Advisors LLC’s holdings in Eli Lilly and Company were worth $217,921,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. Xponance Inc. raised its stake in Eli Lilly and Company by 0.9% in the 4th quarter. Xponance Inc. now owns 191,009 shares of the company’s stock valued at $111,343,000 after purchasing an additional 1,718 shares during the last quarter. AIA Group Ltd increased its stake in shares of Eli Lilly and Company by 2.7% during the 4th quarter. AIA Group Ltd now owns 17,719 shares of the company’s stock valued at $10,329,000 after acquiring an additional 467 shares during the last quarter. Cambridge Trust Co. increased its stake in shares of Eli Lilly and Company by 0.7% during the 4th quarter. Cambridge Trust Co. now owns 10,930 shares of the company’s stock valued at $6,371,000 after acquiring an additional 78 shares during the last quarter. Oliver Lagore Vanvalin Investment Group increased its stake in shares of Eli Lilly and Company by 27.7% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 387 shares of the company’s stock valued at $226,000 after acquiring an additional 84 shares during the last quarter. Finally, Investors Asset Management of Georgia Inc. GA ADV increased its stake in shares of Eli Lilly and Company by 7.6% during the 4th quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 8,894 shares of the company’s stock valued at $5,165,000 after acquiring an additional 630 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.6 %

Shares of Eli Lilly and Company stock traded down $4.82 on Thursday, reaching $745.95. 1,701,333 shares of the company were exchanged, compared to its average volume of 3,067,513. The firm has a market capitalization of $708.77 billion, a price-to-earnings ratio of 129.32, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The stock has a fifty day moving average price of $764.03 and a 200-day moving average price of $657.67.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.09 earnings per share. On average, analysts expect that Eli Lilly and Company will post 12.52 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LLY. Barclays upped their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Citigroup increased their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, BMO Capital Markets increased their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.